文献速递心境障碍

一种新型、简短、全自动的干预延长单次氯胺酮输注的抗抑郁效应:一项随机临床试验

A Novel, Brief, Fully Automated Intervention to Extend the Antidepressant Effect of a Single Ketamine Infusion: A Randomized Clinical Trial.
PubMed 文献 · Am J Psychiatry · 2022-09-21

该双盲平行组随机试验纳入154例难治性单相抑郁成人,比较氯胺酮联合主动自动化自我关联训练(ASAT)、生理盐水联合主动ASAT、氯胺酮联合假ASAT三组。结果显示氯胺酮联合主动ASAT在30天内维持抑郁评分显著稳定降低,而氯胺酮联合假ASAT组评分从24小时至30天显著线性上升。提示氯胺酮后给予积极自我关联训练可延长其快速抗抑郁效应。

要点

  • 氯胺酮联合主动ASAT组在30天内MADRS评分显著稳定低于生理盐水联合主动ASAT组。
  • 氯胺酮联合假ASAT组评分从24小时至30天显著线性上升,接近生理盐水联合主动ASAT组水平。
  • 氯胺酮输注后24小时抑郁评分快速显著下降(组×时间交互β=-1.30)。

核心结论

  • 氯胺酮后给予自动化积极自我关联训练可延长其快速抗抑郁效应的持续时间。

研究设计与样本

  • 双盲、平行组随机临床试验,纳入154例18-60岁难治性单相抑郁成人。
  • 随机分为氯胺酮联合主动ASAT组(N=53)、生理盐水联合主动ASAT组(N=51)、氯胺酮联合假ASAT组(N=50)。
  • 单次静脉氯胺酮0.5 mg/kg over 40分钟或生理盐水后1天开始ASAT或假ASAT,每日两次连续4天共8次,每次≤20分钟。
  • 主要结局为30天内蒙哥马利-Å斯伯格抑郁评定量表(MADRS)评分。

主要发现

  • 氯胺酮在输注后24小时快速显著降低抑郁评分(组×时间交互标准化β=-1.30,95% CI=-1.89, -0.70;t=-4.29,df=150)。
  • 氯胺酮联合主动ASAT组在30天内抑郁评分相对生理盐水联合主动ASAT组显著稳定降低(β=-0.61,95% CI=-0.95, -0.28;t=-3.62,df=148)。
  • 氯胺酮联合假ASAT组从24小时至30天抑郁评分呈显著线性上升,接近生理盐水联合主动ASAT组水平(组×时间交互β=0.015,95% CI=0.003, 0.03;t=2.35,df=568)。

临床怎么用

  • 氯胺酮输注后辅以自动化积极自我关联训练可能延长抗抑郁疗效,且低成本、便携、非侵入、易于推广。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Intravenous ketamine, which displays rapid antidepressant properties, is posited to reverse depression by rapidly enhancing neuroplasticity. The authors tested whether an automated, computer-based approach could efficiently leverage enhanced neuroplasticity to extend the durability of rapid clinical response. METHODS: A total of 154 adults (ages 18-60) with treatment-resistant unipolar depression were randomized in a double-blind, parallel-arm design to receive an active/active treatment combination (ketamine plus active "automated self-association training" [ASAT]; N=53) or one of two control arms that lacked either the active drug component (saline plus active ASAT; N=51) or the active behavioral component (ketamine plus sham ASAT; N=50). One day after a single infusion of intravenous ketamine (0.5 mg/kg over 40 minutes) or inert placebo (saline), active ASAT-targeting self-worth through automated "evaluative conditioning" training delivered by computer-or sham ASAT (consisting of identical computer tasks that included no positive or self-referential stimuli) was given, delivered twice daily over 4 consecutive days (eight sessions, ≤20 minutes per session). The prespecified primary outcome measure throughout the main (30-day) study period was score on the Montgomery-Åsberg Depression Rating Scale (MADRS). RESULTS: Ketamine rapidly and significantly reduced depression scores at 24 hours postinfusion (group-by-time interaction: standardized beta [β]=-1.30, 95% CI=-1.89, -0.70; t=-4.29, df=150). In intent-to-treat linear mixed models, depression scores in the ketamine+ASAT group remained significantly and stably low over the 30-day study period relative to those of the saline+ASAT group (β=-0.61, 95% CI=-0.95, -0.28; t=-3.62, df=148). By contrast, depression scores following ketamine+sham treatment followed a significant, increasing linear trajectory from 24 hours to 30 days, approaching the levels observed in the saline+ASAT group (group-by-time interaction relative to the saline+ASAT group: β=0.015, 95% CI=0.003, 0.03; t=2.35, df=568). CONCLUSIONS: After priming the brain with ketamine, training positive self-associations could provide an efficient, low-cost, portable, noninvasive, and highly dissemination-ready strategy for leveraging and extending ketamine's rapid antidepressant effects.

来源:Am J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Price RB, Spotts C, Panny B, et al. A Novel, Brief, Fully Automated Intervention to Extend the Antidepressant Effect of a Single Ketamine Infusion: A Randomized Clinical Trial. Am J Psychiatry. 2022. PMID: 36128684. doi:10.1176/appi.ajp.20220216

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。